Filing Details
- Accession Number:
- 0000950170-24-062637
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-20 20:35:08
- Reporting Period:
- 2024-05-16
- Accepted Time:
- 2024-05-20 20:35:08
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1650648 | 4D Molecular Therapeutics Inc. | FDMT | Biological Products, (No Disgnostic Substances) (2836) | 473506994 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1920738 | Scott Bizily | C/O 4D Molecular Therapeutics, Inc. 5858 Horton Street #455 Emeryville CA 94608 | Chief Legal Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-05-16 | 500 | $6.49 | 2,237 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-05-16 | 1,250 | $8.04 | 3,487 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-05-16 | 1,283 | $25.34 | 2,204 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-16 | 467 | $25.75 | 1,737 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right To Buy) | Disposition | 2024-05-16 | 500 | $0.00 | 500 | $6.49 |
| Common Stock | Stock Option (Right To Buy) | Disposition | 2024-05-16 | 1,250 | $0.00 | 1,250 | $8.04 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 13,711 | 2032-06-17 | No | 4 | M | Direct | |
| 37,918 | 2032-08-31 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.
- The transaction was executed in multiple trades in prices ranging from $24.67 to $25.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote..
- The transaction was executed in multiple trades in prices ranging from $25.67 to $25.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
- The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Billionaire Hedge Funds
